Grifols (NASDAQ:GRFS) Stock Price Down 2.7% – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) shares fell 2.7% during trading on Friday . The stock traded as low as $7.48 and last traded at $7.51. 203,161 shares were traded during mid-day trading, a decline of 89% from the average session volume of 1,823,070 shares. The stock had previously closed at $7.72.

Analysts Set New Price Targets

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Trading Down 2.7 %

The firm has a market cap of $5.16 billion, a price-to-earnings ratio of 7.74 and a beta of 0.43. The company’s 50-day moving average price is $8.35 and its 200-day moving average price is $8.10. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Institutional Investors Weigh In On Grifols

Several large investors have recently bought and sold shares of GRFS. Hantz Financial Services Inc. purchased a new stake in shares of Grifols during the second quarter worth approximately $1,235,000. Natixis Advisors LLC grew its holdings in shares of Grifols by 116.0% during the second quarter. Natixis Advisors LLC now owns 154,053 shares of the biotechnology company’s stock worth $971,000 after buying an additional 82,723 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Grifols by 56.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 55,887 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 20,120 shares during the last quarter. Black Creek Investment Management Inc. lifted its stake in shares of Grifols by 7.7% in the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after buying an additional 881,155 shares in the last quarter. Finally, Highland Peak Capital LLC acquired a new position in Grifols during the second quarter worth about $5,991,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.